Greenleaf Trust Grows Position in United Therapeutics Co. (NASDAQ:UTHR)

Greenleaf Trust raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 11.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,289 shares of the biotechnology company’s stock after acquiring an additional 133 shares during the quarter. Greenleaf Trust’s holdings in United Therapeutics were worth $283,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Comerica Bank grew its stake in United Therapeutics by 2,697.2% during the 3rd quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock worth $35,368,000 after buying an additional 150,989 shares during the last quarter. Pacer Advisors Inc. grew its position in shares of United Therapeutics by 27.6% during the fourth quarter. Pacer Advisors Inc. now owns 312,799 shares of the biotechnology company’s stock worth $68,781,000 after acquiring an additional 67,738 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec grew its position in shares of United Therapeutics by 30.9% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 260,412 shares of the biotechnology company’s stock worth $58,819,000 after acquiring an additional 61,543 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in shares of United Therapeutics by 840.1% in the 3rd quarter. Glenmede Trust Co. NA now owns 68,098 shares of the biotechnology company’s stock valued at $15,381,000 after acquiring an additional 60,854 shares during the period. Finally, Robeco Institutional Asset Management B.V. increased its stake in United Therapeutics by 125.2% in the third quarter. Robeco Institutional Asset Management B.V. now owns 87,048 shares of the biotechnology company’s stock valued at $19,662,000 after purchasing an additional 48,397 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on UTHR shares. HC Wainwright reaffirmed a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. Wedbush reissued an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. SVB Leerink initiated coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price for the company. Finally, The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $294.25.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $236.47, for a total transaction of $851,292.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $30,741.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $236.47, for a total value of $851,292.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,741.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares of the company’s stock, valued at approximately $7,880,130.69. The disclosure for this sale can be found here. Insiders have sold a total of 133,390 shares of company stock valued at $31,379,925 over the last quarter. Company insiders own 12.50% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $237.00 on Thursday. The stock has a fifty day moving average price of $232.93 and a 200 day moving average price of $228.74. United Therapeutics Co. has a 52 week low of $204.44 and a 52 week high of $261.54. The firm has a market capitalization of $11.15 billion, a P/E ratio of 11.95 and a beta of 0.52. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same period in the prior year, the firm posted $2.67 EPS. The company’s revenue was up 25.1% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Co. will post 23.45 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.